{"analyses":[{"ciLowerLimit":"0.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.21","groupDescription":"Comparison of EGFR positive populations","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6198","paramType":"Hazard Ratio (HR)","paramValue":"0.94","statisticalMethod":"Log Rank","testedNonInferiority":false},{"ciLowerLimit":"0.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.62","groupDescription":"Comparison of EGFR negative populations","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8398","paramType":"Hazard Ratio, log","paramValue":"0.95","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"7.5","value":"5.5"},{"groupId":"OG001","lowerLimit":"4.0","upperLimit":"7.6","value":"5.6"}]}],"title":"EGFR Positive (n=149,143)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"11.5","value":"6.7"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"7.8","value":"5.4"}]}],"title":"EGFR Negative (n=39,32)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"175"}],"units":"Participants"}],"description":"EGFR is a gene in the tumor tissues and mutations in this gene have been linked to a variety of tumors. Presence or absence of EGFR was determined by IHC. OS was determined from the date of randomization to the date of death irrespective of the cause of death in EGFR positive and negative populations. Kaplan-Meier estimates were used for analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received either pemetrexed 500 mg/m\\^2 every 21 days until disease progression, unacceptable toxicity or death or docetaxel 75 mg/m\\^2 every 3 weeks until disease progression, unacceptable toxicity or death. Choice of comparator was left to the discretion of the investigator in countries where both treatments are registered to use and are commercially available for second line use (otherwise, docetaxel was administered), assigning the participant to either comparator depending upon the medical needs of the participant. Participants were required to receive concomitant treatment therapy as indicated in the product label.","id":"OG000","title":"Comparator"},{"description":"Participants received erlotinib, 150 mg, administered orally as a tablet, once daily until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Erlotinib"}],"paramType":"MEDIAN","populationDescription":"FAS population; Only participants with confirmed presence or absence of EGFR were included in the analysis. n=number of participants who were EGFR positive or negative","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 3 and 6, Every 3 Weeks until Week 48 and Every 12 Weeks until Death or Until Data Cut off (07 September 2010) up to 52 months","title":"Duration of OS in EGFR Positive and Negative Population","type":"SECONDARY","unitOfMeasure":"months"}